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Abstract
Background: In Europe, synthetic corticosteroids are not allowed in animal breeding for growth-promoting
purposes. Nevertheless, a high prevalence of non-compliant urine samples was recently reported for prednisolone,
however, without any indication of unauthorized use. Within this context, 20β-dihydroprednisolone and the
prednisolone/cortisol ratio have been suggested as potential tools to discriminate between exogenous and
endogenous urinary prednisolone. In this study, the validity of these strategies was verified by investigating the
plasma pharmacokinetic and urinary excretion profiles of relevant glucocorticoids in bovines, subjected to
exogenous prednisolone treatment or tetracosactide hexaacetate administration to induce endogenous
prednisolone formation. Bovine urine and plasma samples were analysed by liquid chromatography and mass
spectrometry.
Results: Based on the plasma pharmacokinetics and urinary profiles, 20β-dihydroprednisolone was confirmed as
the main prednisolone-derived metabolite, being detected in the biological fluids of all 12 bovines (plasma AUC0-inf
of 121 h μg L−1 and urinary concentration > 0.695 μg L−1). However, this metabolite enclosed no potential as
discriminative marker as no significant concentration differences were observed upon exogenous prednisolone
treatment or tetracosactide hexaacetate administration under all experimental conditions. As a second marker tool,
the prednisolone/cortisol ratios were assessed along the various treatments, taking into account that endogenous
prednisolone formation involves the hypothalamic-pituitary-adrenal axis and is associated with an increased cortisol
secretion. Significantly lower ratios were observed in case of endogenous prednisolone formation (i.e. ratios ranging
from 0.00379 to 0.129) compared to the exogenous prednisolone treatment (i.e. ratios ranging from 0.0603 to 36.9).
On the basis of these findings, a discriminative threshold of 0.260 was proposed, which allowed classification of
urine samples according to prednisolone origin with a sensitivity of 94.2% and specificity of 99.0%.
Conclusion: The prednisolone/cortisol ratio was affirmed as an expedient strategy to discriminate between
endogenous and exogenous prednisolone in urine. Although the suggested threshold value was associated with
high specificity and sensitivity, a large-scale study with varying experimental conditions is designated to optimize
this value.
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Background
Synthetic glucocorticoids are extensively employed in
cattle for therapeutic purposes because of their well-
recognized anti-inflammatory and immunosuppressive
properties. Among these glucocorticoids, the most com-
monly used are dexamethasone methylprednisolone, and
prednisolone. For example, the latter is frequently used
in cattle, including dairy cows, for the treatment of aller-
gic dermatitis, otitis, pruritus and musculoskeletal
inflammation [1, 2]. Apart from the therapeutic applica-
tions, synthetic glucocorticoids may also be administered
unauthorized to promote the growth of veal calves, fin-
ishing bulls and cows at the end of their production
cycle [3]. Glucocorticoids tend to increase live weight
gain, improve feed intake, reduce the feed conversion ra-
tio, reduce nitrogen retention, increase the fat content
and promote water retention [4]. As such, growth-
promoting effects have been demonstrated for beef cattle
after oral administration of prednisolone acetate (15–
30 mg per animal per day) for 30–35 days [5]. Because
of the strong pharmacological activity, the residues of
most synthetic corticosteroids might impose a risk for
food safety. Therefore, to protect consumer’s health, the
administration of synthetic glucocorticoids in livestock is
restricted to therapeutic applications only and should be
done by a licensed veterinarian [6]. Moreover, appropri-
ate withdrawal times have been defined for glucocortic-
oid treatment in order to comply with the maximum
residue limits (MRLs), as they have been established for
bovine edible tissues [6, 7].
In the past few years, the European Commission re-
ported a higher prevalence of non-compliant urine sam-
ples for prednisolone [8–11], without any direct evidence
of unauthorized use. Therefore, in order to account for
potential endogenous prednisolone, the European Refer-
ence Laboratories have proposed a threshold level for
urinary prednisolone in bovine urine of 5 μg L−1 [12, 13].
However, such an artificial cut-off value may still leave the
possibility for false accusations or legalization of low-level
prednisolone abuse. In this regard, alternatives to
discriminate between exogenous and endogenous prednis-
olone have been suggested, i.e. usage of the prednisolone/
cortisol urinary concentration ratio and analysis of
20β-dihydroprednisolone [14–17], although both have not
been confirmed or validated yet. Therefore, in this study,
to verify the applicability and validity of these screen-
ing tools, the pharmacokinetics and urinary excretion
profiles of prednisolone, prednisone, 20α- and 20β-
dihydroprednisolone were assessed during a growth-
promoting and therapeutic prednisolone treatment
(Additional file 1). Moreover, also a pharmacologically-
induced stress treatment was considered as it has recently
been evidenced that stress induction with a synthetic
analogue of the adrenocorticotropic hormone (ACTH), i.e.
tetracosactide hexaacetate, leads to the presence of endogen-
ous prednisolone in bovine urine. In addition, the overall
cortisol secretion during growth-promoting, therapeutic
prednisolone, and ACTH treatment was assessed by profiling
natural urinary glucocorticoid metabolites, i.e. cortisone,
dihydrocortisone, corticosterone, deoxycorticosterone, allote-
trahydrocortisol, tetrahydrocortisone, urocortisol, α-
cortolone and 6β-hydroxycortisol. To date, only a few studies
have been dedicated to correlate endogenous (e.g. cortisol)
and exogenously administered glucocorticoids (e.g. dexa-
methasone, prednisolone) as a means to estimate the degree
of glucocorticoid resistance or super sensitivity [18–20].
Nevertheless, a deepened knowledge on these correlations is
believed to support the understanding of endogenous
formation mechanisms and might yield an adequate screen-
ing tool.
Methods
Test animals
Twelve clinically healthy cows of a mixed breed were
housed under controlled experimental conditions at the
animal facilities of Centre d’Economie Rurale (CER,
Marloie, Belgium). These cows were 2 to 6 years of age
and had a body weight between 370 and 600 kg. They
were fed a commercial diet, with ad libitum access to
water and hay. During the entire study, animals were
kept in three separate groups (4 animals per group), all
housed in a half-covered pen. Prior to the in vivo study,
an initial acclimatization period of 10 days was foreseen,
allowing adaptation to the environmental and feeding
conditions. This study was approved by CER’s Ethical
Committee (CE/Sante/ET/004).
Experimental protocol
After acclimatization (Fig. 1A), animals were subjected
to a similar oral (per os, PO) and intramuscular (IM)
prednisolone treatment sequence. First, a growth-
promoting treatment (long-term, 40 mg per cow a day,
PO and IM) was applied, followed by a therapeutic treat-
ment (short-term, 0.5 mg per kg bodyweight a day, PO
and IM) (Fig. 1A). Then, a washout period of 11 weeks
was incorporated, after which tetracosactide hexaacetate
(2 mg per day) was administered intramuscularly for
4 days to mimic stress (Fig. 1B). All types of treatment
were executed at 8 h in the morning.
Phase I: Prednisolone treatments
The growth-promoting treatment started with 30 con-
secutive days of PO administration of 40 mg per day of
prednisolone in capsules (prednisolone, Fagron,
Belgium) (Day + 1 till Day + 30), followed by a washout
period of 10 days. Next, IM injections of 40 mg per day
of Solu-Delta-Cortef® (prednisolone sodium succinate,
Zoetis, Belgium) were given for 30 consecutive days
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(Day + 41 till Day + 70). Before the start of the thera-
peutic prednisolone treatment, a washout period of
35 days was foreseen.
During the therapeutic treatment, a similar experi-
mental set-up was implemented. First, the animals re-
ceived 0.5 mg prednisolone per kg body weight PO for
5 days (Day + 106 till Day + 110), which was followed
by a washout period of 25 days. Next, IM injections of
0.5 mg of Solu-Delta-Cortef® per kg body weight were
given during 5 consecutive days (Day + 136 till
Day + 140). Until 32 days (Day + 141 till Day + 172)
after the last prednisolone administration, urine samples
were collected in order to monitor the reconversion to
the natural glucocorticoid body state.
Phase II: ACTH treatment
After phase I, a washout period of 11 weeks was consid-
ered. Subsequently, all animals received IM injections of
2 mg tetracosactide hexaacetate (Utrecht University, Faculty
of Veterinary Medicine, Utrecht, The Netherlands), corre-
sponding to 200 I.U. of ACTH, during 4 consecutive days.
Sample collection
During prednisolone treatments, urine samples were each
time collected in the morning, prior to prednisolone ad-
ministration. These samples were obtained by a veterinar-
ian using a probe (to prevent faecal contamination) and
were immediately portioned into 15-mL tubes, which
were then stored in the dark at −80 °C until analysis. Dur-
ing the growth-promoting treatment, samples were col-
lected every five days whereas during the therapeutic
treatment, urine samples were collected the first, third
and last day. In addition, samples were also collected every
day during the acclimatization period and every five days
during the washout periods. Also, urine samples were col-
lected twice a day during the ACTH treatment period,
whereby samples were collected prior to and at 4 h
(Day + 1 and Day + 2) or at 6 h (Day + 3 and Day + 4)
after tetracosactide hexaacetate administration.
Blood samples were collected in the morning, thereby
applying a similar sampling strategy as for urine. In
addition, blood samples for pharmacokinetic analysis were
collected at the beginning and end of each treatment
period at time 0 (just before administration), 15 min,
30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h (post-ad-
ministration). With each collection, 5 mL of blood was
sampled into heparin tubes. One hour after collection,
blood was centrifuged at 600 x g during 15 min at 4 °C
and divided into 2-mL plasma aliquots, which were then
immediately stored at −20 °C until analysis.
Reagents and chemicals
Standards of prednisolone, prednisone, cortisone, corti-
sol, dihydrocortisone, aldosterone, allotetrahydrocortisol,
urocortisol, tetrahydrocortisone, corticosterone, deoxy-
corticosterone, α-cortolone and 6β-hydroxycortisol were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Internal standards were prednisolone-d8 (TRC, Canada),
cortisol-d4 and prednisolonde-d4 (Sigma-Aldrich). Re-
agents were of analytical grade (Merck, Darmstadt,
Germany) when used for extraction purposes and of
liquid chromatography-mass spectrometry (LC-MS)
Optima grade (Fisher Scientific, Loughborough, UK) for
ultra-high performance LC (UHPLC) tandem MS (MS/
MS) and high-resolution MS (HRMS) applications.
Ultrapure water was obtained by usage of a purified-
water system (Sartorius AG, Goettingen, Germany). Stock
solutions were prepared in ethanol at a concentration of
200 μg mL−1 and stored in dark glass bottles at −20 °C.
Sample preparation
Urine
A detailed description of the analytical procedure, which
was used for glucocorticoid extraction from urine, has
Fig. 1 Schematic representation of the in vivo study. The various experimental treatments include oral (PO) and intramuscular (IM) prednisolone
administration (a) and the treatment with tetracosactide hexaacetate, a synthetic analogue of ACTH (b). The wash-out periods are indicated in
blue. This experimental procedure was implemented to each of the test animals (n = 12)
Van Meulebroek et al. BMC Veterinary Research  (2017) 13:236 Page 3 of 12
been given in earlier work [21]. In brief, 5 mL of urine
was enriched with the internal standards cortisol-d4 and
prednisolone-d8 to reach final concentration of 10 μg L
−1. Next, a twofold liquid-liquid extraction with tert-
butyl methyl ether was applied, whereby the organic
phases were collected, pooled and dried under a gentle
stream of nitrogen at 50 °C. The residue was then dis-
solved in 100 μL of initial mobile phase conditions and
transferred into an LC- vial.
Plasma
Two mL of vortexed plasma was spiked with the internal
standards cortisol-d4 and prednisolone-d4 to obtain final
concentrations of 10 μg L−1. Glucocorticoids were ex-
tracted by liquid-liquid extraction, thereby using 5 mL
acetonitrile. After 30 min of extraction, samples were
centrifuged at 3760 x g for 10 min at 10 °C. Then, the
supernatants were collected and evaporated under a
gentle stream of nitrogen at 40 °C. The residue was sus-
pended in 200 μL of water-acetonitrile (80/20, v/v) and
transferred into an LC-vial.
Mass spectrometric detection
UHPLC-Orbitrap MS for urine
Glucocorticoid analysis of urine was performed by
UHPLC-Orbitrap MS, according to the method of De
Clercq et al. (2013) [21]. Chromatographic separation of
the target analytes was thereby achieved using an Accela
UHPLC system (Thermo Fisher Scientific, San José,
USA), equipped with a Nucleodur Isis C18 column
(1.8 μm, 100 mm × 2 mm, Macherey-Nagel, Düren,
Germany). High-resolution mass spectrometric analysis
was performed with an Exactive™ single-stage Orbitrap
mass spectrometer (Thermo Fisher Scientific), equipped
with a heated electrospray ionization probe (HESI II),
operating in polarity switching mode. Instrument control
and data processing were carried out by Xcalibur 2.1
software (Thermo Fisher Scientific, San José, USA).
UHPLC-MS/MS analysis for plasma
The chromatographic analysis of glucocorticoids in
plasma was performed by a Waters Acquity system (Wa-
ters, Manchester, UK) according to Delahaut et al.
(2014) [16]. Chromatographic separation of the target
analytes was thereby achieved using an Acquity C18 col-
umn (1.7 μm, 125 × 3 mm). Mass spectrometric analysis
was performed with a Xevo TSQ tandem mass spec-
trometer (Waters Corporation, Manchester, UK), operat-
ing in the positive ion electrospray mode and applying
multiple reaction monitoring (MRM). For each target
compound, two transitions were monitored (Additional
file 2), the first being the quantifier and the second being
the qualifier. For quantification, two internal standards
were used: prednisolone-d4 and cortisol-d4. Instrument
control and data processing were carried out by Mas-
sLynx and QUANLYNX software (Waters Corporation,
Manchester, UK) respectively.
A brief validation of the newly developed method for
glucocorticoid analysis of plasma was performed based
on Commission Decision 2002/657/EC guidelines [22].
The method performance in terms of repeatability,
within-laboratory reproducibility, recovery, CCα and spe-
cificity was thereby assessed. Plasma samples that were
used for validation were obtained from non-medicated
cows (n = 3), which were housed at the animal facilities
of CER. Linearity was evaluated based on eight-point
matrix-matched calibration curves with concentration
levels ranging from 0.25 to 20 μg L−1 for prednisolone,
prednisone, 20α-dihydroprednisolone, and 20β-
dihydroprednisolone and from 0.5 to 40 μg L−1 for corti-
sol, cortisone, and dihydrocortisone. Repeatability was
determined by analysis of samples that were spiked with
the target compounds, thereby considering seven repli-
cates for two different concentration levels, i.e. 0.50 and
5 μg L−1 for prednisolone, prednisone, 20α-
dihydroprednisolone, and 20β-dihydroprednisolone and
1 and 10 μg L−1 for cortisol, cortisone, and dihydrocorti-
sone. For evaluation of the within-laboratory reproduci-
bility, the specified analyses were performed on two
different occasions, with a different operator on the
second occasion. The CCα was derived from chromato-
grams and corresponded to a concentration giving a
peak with a signal-to-noise ratio of 3. Specificity was
evaluated by analyzing a potential interfering substance
(methylprednisolone) to verify potential cross-talk
during analysis.
Quantitation and normalization
Due to the broad concentration range expected in the
urine samples during the different prednisolone treat-
ments, quantitation of the various urinary glucocorticoid
compounds was based on two eight-point calibration
curves (using area ratios), which were prepared in urine
matrix. Samples were thereby fortified with all gluco-
corticoid standards to reach concentrations from 0.50 to
75 ng mL−1 and from 100 to 200 ng mL−1 for cortisol,
cortisone, dihydrocortisone, prednisolone, prednisone,
methylprednisolone, 20α-dihydroprednisolone, and 20β-
dihydroprednisolone. The employed urine matrix was
previously verified to contain no residues of prednisol-
one, prednisone, 20α-dihydroprednisolone and 20β-
dihydroprednisolone, but the other glucocorticoids were
found to be endogenously present. Therefore, the
endogenous concentration levels of cortisol, cortisone,
and dihydrocortisone were determined as the average of
five non-fortified urine samples and taken into account
during quantitation. In addition, since urine is a matrix
prone to dilution, normalization by means of the specific
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gravity (Pocket Refractometer™, Atago, Tokyo) was ap-
plied using the Levine-Fahy eq. [23].
Pharmacokinetic analysis
Pharmacokinetic analysis was performed with WinNonlin
6.3 (Pharsight Corporation, St-Louis, USA). Plasma
concentration-time profiles were modeled using a one-
compartmental model for PO and a two-compartmental
model for IM prednisolone administration. The most im-
portant pharmacokinetic parameters were the peak
plasma concentration (Cmax), time to reach the peak
plasma concentration (Tmax), area under the plasma
concentration-time curve from time 0 to time inf (AUC0-
inf ), absorption rate constant (ka), absorption half-life (T1/
2a), apparent clearance (Cl/F) and apparent volume of dis-
tribution (Vd/F). Additionally, for two-compartmental
methods, the distribution rate constant (kelα), the elimin-
ation rate constant (kelβ) and elimination half-life (T1/2elβ)
were also determined. The coefficient of determination
(R2) was hereby used as an indicator for the goodness-of-
fit. For the main metabolites, only Cmax, Tmax, AUC0-inf,
kel en T1/2el were calculated.
Statistical analysis
All pharmacokinetic parameters were compared between
administration routes according to dose (therapeutic and
growth-promoting), thereby using one-way analysis of
variance (ANOVA) (p-value ≤ 0.05) (SPSS 21, IBM,
USA). Urinary concentrations were statistically evaluated
using Student’s t-test and one-way ANOVA with post-
hoc Tukey’s multiple comparisons test.
Results
Method validation
For each of the targeted compounds, the determination
coefficient (R2) was above 0.99 for all three calibration
curves, established in plasma and analyzed on three dif-
ferent days. The other performance characteristics of the
validation are presented in Additional file 3. Recoveries
ranged from 92 to 107%. Repeatability and within-
laboratory reproducibility were evaluated based on the
coefficients of variation (RSD) and were below the 15%-
tolerance level, specified in CD 2002/657/EC [22], except
for 20α-dihydroprednisolone (22.3% at 0.5 μg L−1),
which was nevertheless considered acceptable because of
the low target concentration.
Pharmacokinetics of prednisolone and its metabolites
The pharmacokinetic parameters were determined for
plasma prednisolone during the growth-promoting and
therapeutic treatments (Fig. 2. A), thereby using a one-
(PO) or two-compartmental (IM) model. A growth-
promoting (40 mg day−1) and therapeutic (0.5 mg kg
−1 day−1) PO administration of prednisolone in cattle
resulted in a relatively fast absorption with Cmax being
reached within 2.95 h and 3.85 h (Tmax), respectively
(Table 1). Evidently, prednisolone absorption in case of
IM administration was much faster, with Tmax ranging
from 0.168 to 0.866 h. The absorption (T1/2a) and elim-
ination half-life (T1/2el) for unbound prednisolone after
PO and IM administration was considered rather inde-
pendent of dose, although the highest IM dose (0.5 mg
kg−1 day−1) showed a somewhat increased T1/2el. The
Vd/F for oral administered prednisolone increased from
11.95 to 30.06 L kg−1 during, respectively, growth-
promoting and therapeutic treatment. The same effect
was noticed during the two types of IM prednisolone
administration.
Pharmacokinetic parameters (one-compartmental) of the
main prednisolone metabolites, i.e. prednisone, 20α-, and
20β-dihydroprednisolone, were only considered for the IM
therapeutic prednisolone treatment (Table 2) as plasma
concentration levels were below the associated CCα for all
these metabolites during oral therapeutic treatment and
growth-promoting treatments (PO and IM). Based on the
AUC0-inf, it was determined that 20β-dihydroprednisolone
is the most abundant prednisolone-derived metabolite in
plasma. Additionally, 20β-dihydroprednisolone could be
detected already 15 min after IM prednisolone administra-
tion. Maximum plasma concentration levels for this metab-
olite were reached about 2 h after start of the treatment
(Fig. 2. B). For prednisone, a similar Tmax was observed as
for prednisolone (0.857 h and 0.866 h, respectively), indicat-
ing a very fast conversion of prednisolone into prednisone
by the 11β-hydroxysteroid dehydrogenase type 2 enzyme in
the liver [24].
During tetracosactide hexaacetate administration,
traces of prednisolone in plasma could be detected,
but were below CCα. As reliable quantification is
hereby not possible, pharmacokinetic parameters were
not determined.
Urinary excretion profile of prednisolone and its metabolites
Growth-promoting treatment
Based on the analysis of the urine samples that were
collected prior to prednisolone administration, it was
verified that prednisolone, prednisone, 20α-, and 20β-
dihydroprednisolone were not endogenously present at
detectable concentration levels. After five days of oral
prednisolone treatment (40 mg day−1), urinary prednis-
olone reached an average concentration of 0.832 ± 0.38
μg L−1. When animals were given a same dose by
intramuscular injection, an average prednisolone
concentration of 1.16 ± 1.08 μg L−1 was reached. These
urinary prednisolone concentrations are below the
threshold of 5 μg L−1, suggested by the EURL. During
the following 25 days, the urinary prednisolone concen-
trations remained rather constant for both treatments.
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Eventually, 24 h after the growth-promoting treatment
was ended, prednisolone concentrations started to de-
crease. Undetectable levels were reached after 5 days,
which appeared to be independent of the administra-
tion route.
During growth-promoting treatment, prednisolone
and 20β-dihydroprednisolone were detected in all urine
samples, whereas 20α-dihydroprednisolone was only
present in the urine of 8 out of 12 animals (Table 3. A).
Prednisone was not detected in any urine sample when
prednisolone was administered orally, being in contrast
with intramuscular injection where prednisone was de-
tected in the urine samples from 4 animals. The major
prednisolone metabolite, i.e. 20β-dihydroprednisolone,
was found until 24 h after the end of the IM treatment,
with undetectable levels after five days.
Therapeutic treatment
After three days of PO and IM therapeutic administration
of prednisolone, mean urinary prednisolone concentra-
tions of respectively 0.922 μg L−1 and 20.1 μg L−1 were re-
trieved. After two more days of IM injection, the urinary
average prednisolone concentration further increased to
42.4 μg L−1, whereas the concentration remained rather
constant in case of oral treatment. After ending the PO
treatment, the urinary excretion profile of prednisolone
revealed a very strong decrease. Indeed, within 48 h after
final administration, prednisolone concentration levels
were diminished with almost 80%. Eventually, after 5 days,
no more prednisolone could be detected at concentration
levels above the CCα. For IM injection, prednisolone con-
centrations above the CCα were observed in two animals
up to 10 days after final treatment.
Fig. 2 a Plasma concentration profile for prednisolone, as observed after growth-promoting or therapeutic prednisolone administration. Results are
expressed as mean plasma concentration levels ± SD (n = 12). The growth-promoting and therapeutic treatment are represented by black and white
symbols, respectively. Hereby, a distinction is made between oral (circle) and intramuscular (triangle) prednisolone administration. b Plasma concentration
profile for prednisolone, 20β-dihydroprednisolone, prednisone, and 20α-dihydroprednisolone as observed after intramuscular therapeutic administration.
Results are expressed as mean plasma concentration levels ± SD (n = 12). Prednisolone is represented by black circles, 20β-dihydroprednisolone by white
circles, prednisone by white triangles and 20 α-dihydroprednisolone by black triangles
Table 1 Pharmacokinetic parameters for prednisolone after oral and intramuscular administration during growth-promoting and
therapeutic treatment
Oral treatment Intramuscular treatment
40 mg day−1 0.5 mg kg−1 day−1 40 mg day−1 0.5 mg kg−1 day−1
Cmax (μg L−1) 2.96 ± 1.50 7.01 ± 1.52 117 ± 25.8 156 ± 78.1
Tmax (h) 2.95 ± 0.820 3.85 ± 0.909 0.168 ± 0.063 0.866 ± 0.273
AUC0-tinf (h μg L−1) 26.1 ± 19.1 75.5 ± 25.0 232 ± 17.5 678 ± 11.5
ka (h
−1) 0.363 ± 0.099 0.307 ± 0.129 17.1 ± 11.2 1.93 ± 0.395
T1/2a (h) 2.05 ± 0.588 2.53 ± 0.854 0.064 ± 0.052 0.370 ± 0.083
kel (h
−1) 0.362 ± 0.091 0.245 ± 0.053 0.325 ± 0.046 0.132 ± 0.092
T1/2el (h) 2.04 ± 0.553 2.97 ± 0.728 2.16 ± 0.308 3.80 ± 0.499
Vd/F (L kg−1) 11.9 ± 4.89 30.1 ± 9.98 0.503 ± 0.215 2.47 ± 1.61
Cl/F (L h−1 kg−1) 4.66 ± 2.68 7.15 ± 1.97 0.346 ± 0.026 0.737 ± 0.012
Average parameter values and SD were determined on the basis of 12 samples. Therapeutic treatment concerned the administration of 0.5 mg prednisolone kg
−1 day−1, whereas during growth-promoting treatment 40 mg day−1 was administered
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During PO administration of prednisolone, all urine sam-
ples contained prednisolone and 20β-dihydroprednisolone,
whereas prednisone and 20α-dihydroprednisolone could
only be detected in 2 and 8 animals, respectively. For IM
prednisolone injection, all target glucocorticoids were
detected in the urine samples of all animals (Table 3B). At
the end of the therapeutic treatment, 20β-
dihydroprednisolone could be detected in urine up to
24 h and 5 days for PO and IM prednisolone treatment,
respectively. The other metabolites were not found after
ending PO administration and only until 24 h after ending
the IM treatment.
ACTH treatment
The synthesis of various glucocorticoids may be induced
by treatment with tetracosactide hexaacetate, affecting
Table 2 Pharmacokinetic parameters for prednisone, 20α-dihydroprednisolone and 20β-dihydroprednisolone after intramuscular
administration during therapeutic prednisolone treatment
Prednisone 20α-dihydroprednisolone 20β-dihydroprednisolone
Cmax (μg L
−1) 13.3 ± 2.56 1.64 ± 0.677 19.2 ± 4.31
Tmax (h) 0.857 ± 0.136 1.42 ± 0.413 2.17 ± 0.571
AUC0-inf (h μg L−1) 58.5 ± 12.1 7.07 ± 3.33 121 ± 26.9
kel (h
−1) 0.307 ± 0.101 0.553 ± 0.184 0.349 ± 0.086
T1/2el (h) 2.43 ± 0.649 1.53 ± 1.02 2.09 ± 0.522
Average parameter values and SD were determined on the basis of 12 samples. Intramuscular therapeutic treatment concerned the injection of 0.5 mg
prednisolone kg−1 day−1
Table 3 Urinary prednisolone, prednisone, 20α-dihydroprednisolone and 20β-dihydroprednisolone concentrations during
growth-promoting and therapeutic prednisolone treatment
Prednisolone Prednisone 20α-dihydroprednisolone 20β-dihydroprednisolone
A1. Oral growth-promoting treatment
N° positive 12 0 8 12
Cmin (μg L
−1) 0.027 - 0.153 0.695
Cmax (μg L
−1) 1.17 - 3.41 14.10
Mean (μg L−1) 0.832 - 0.771 4.35
SD (μg L−1) 0.381 - 0.544 2.44
A2. Intramuscular growth-promoting treatment
N° positive 12 4 8 12
Cmin (μg L−1) 0.014 0.030 0.138 0.938
Cmax (μg L−1) 8.44 2.17 1.79 14.2
Mean (μg L−1) 1.16 0.311 0.472 4.91
SD (μg L−1) 1.08 0.413 0.308 3.15
B1. Oral therapeutic treatment
N° positive 12 2 8 12
Cmin (μg L−1) 0.038 0.033 0.156 1.07
Cmax (μg L−1) 1.36 0.306 2.85 15.15
Mean (μg L−1) 0.922 0.125 0.552 5.13
SD (μg L−1) 0.428 0.108 0.635 1.20
B2. Intramuscular therapeutic treatment
N° positive 12 12 12 12
Cmin (μg L
−1) 0.528 1.08 3.32 8.97
Cmax (μg L
−1) 189 22.5 127 100
Mean (μg L−1) 31.3 8.17 14.9 37.9
SD (μg L−1) 40.7 5.91 26.0 25.0
For each of the treatment set-ups (A1, A2, B1, B2), 12 bovines were considered. In case that a glucocorticoid was not found in the urine samples of all animals,
means ± SD were determined based on the positive urine samples only
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the hypothalamic-pituitary-adrenal axis. In this study, de-
tectable concentration levels of prednisolone, prednisone,
20β-dihydroprednisolone and 20α-dihydroprednisolone
were observed under this pharmacologically-induced
stress. Hereby, concentration levels for prednisolone in
urine ranged from 0.120 to 6.45 μg L−1 (average 1.45 μg L
−1), 4 h after tetracosactide hexaacetate administration
(Day + 1 and Day + 2). After 6 h, prednisolone concentra-
tion levels were significantly lower (p-value ≤ 0.05), al-
though still detectable with a concentration range from
0.169 to 0.729 μg L−1 (average 0.318 μg L−1). The metabo-
lites prednisone, 20α-, and 20β-dihydroprednisolone were
also detected, 4 h after tetracosactide hexaacetate adminis-
tration (Day + 1 and Day + 2), showing concentrations that
ranged from 0.697 to 14.4 μg L−1 (average 3.51 μg L−1),
3.31 to 19.1 μg L−1 (average 6.31 μg L−1), and 0.407 to 33.2
μg L−1 (average 8.12 μg L−1), respectively. At 6 h after treat-
ment (Day + 3 and Day + 4), the metabolite concentrations
were 2 to 3 times lower, but still present at detectable levels
in the urine from all animals. Eventually, 24 h after the last
tetracosactide hexaacetate administration, no residues of
prednisolone or its metabolites could be detected.
In this study, urinary 20β-dihydroprednisolone was
thus detected upon growth-promoting (PO and IM)
prednisolone treatment as well as in the pharmacologic-
ally-induced stress situation (Fig. 3). Hereby, no significant
differences (p ≥ 0.05) were observed between the 20β-
dihydroprednisolone concentrations after PO or IM pred-
nisolone administration and those determined at 6 h post-
ACTH treatment. This is not the case when the urinary
concentrations are considered 4 h after administration of
tetracosactide hexaacetate, showing a significant difference
(p ≤ 0.05).
Urinary excretion profile of natural glucocorticoids
Acclimatization
During the acclimatization period, the three most abun-
dant steroids in urine were cortisol (ranging from 0.411
to 4.26 μg L−1, average 1.79 μg L−1), cortisone (ranging
from 0.472 to 5.53 μg L−1, average 2.68 μg L−1) and dihy-
drocortisone (ranging from 0.222 to 9.36 μg L−1, average
2.27 μg L−1). Other steroids and associated metabolites
were detected at significantly lower concentrations.
Growth-promoting and therapeutic treatment
The relative intensity changes of the target natural me-
tabolites during the various treatments are visualized by
a heat map (Fig. 4). It was hereby noted that the inten-
sity of most metabolites showed a steady decrease when
prednisolone dose increased.
When a growth-promoting dose of prednisolone was
administered, regardless of the administration route, a
significant decrease (p-value ≤ 0.05) of the urinary
concentration was observed for cortisol, cortisone, dihy-
drocortisone, and deoxycorticosterone (i.e. compared to
Blank). After ending the growth-promoting treatment, it
took 5 days before cortisol and its associated metabolites
reached their basal concentration levels again.
During therapeutic administration, a 2- to 5-fold in-
tensity decrease for the urinary metabolites was noticed
for the oral treatment, whereas during IM therapeutic
treatment, almost no residues of the glucocorticoids
dihydrocortisone, allotetrahydrocortisol, corticosterone,
deoxycorticosterone, 6β-hydrocycortisol and α-cortolone
remained (p-values ≤ 0.05, i.e. compared to Blank). It
took 12 days after ending the therapeutic treatment, be-
fore cortisol and its metabolites reached their basal con-
centration levels again.
ACTH treatment
Urinary glucocorticoid profiles were evaluated during
the first 2 days of ACTH treatment. It was thereby con-
cluded that treatment with tetracosactide hexaacetate re-
sulted in significantly (p-value ≤ 0.05) increased urinary
secretion of cortisol, cortisone, dihydrocortisone, tetra-
hydrocortisol, 6β-hydrocycortisol and α-cortolone (Fig.
4). The most intense increases were noticed for cortisol
(70-fold), cortisone (40-fold), and 6β-hydrocycortisol
(35-fold). In addition, the mineralocorticoid aldosterone
was evaluated as well [25], but showed only a 1.5-fold
increase, which is much less than the observed 70-fold
increase of cortisol.
Discussion
In this study, it was aimed to verify the validity of the
prednisolone/cortisol ratio and capacity of 20β-
dihydroprednisolone to discriminate between endogen-
ous and exogenous urinary prednisolone [16, 19].
Fig. 3 Urinary concentration profile of 20β-dihydroprednisolone
during growth-promoting and ACTH administration. Concentrations
of 20β-dihydroprednisolone (20β-DHP) are log-transformed and
presented for the oral (PO1) and intramuscular (IM1) growth-promoting
treatment, as well as for the ACTH treatment (with sampling moments at
4 h and 6 h after administration)
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Indeed, there is a strong need for an adequate screening
and confirmation tool that is able to unambiguously af-
firm the origin of detected prednisolone as the EURL
suggested discriminative threshold value of 5 μg L−1 [12,
13] is not fully conclusive. This was also evidenced in
this study as urinary prednisolone concentrations were
frequently below this threshold during both growth-
promoting and therapeutic treatment. In this context,
the above-mentioned screening strategies were compre-
hensively assessed by evaluating the urinary profiles and
plasma pharmacokinetics of relevant glucocorticoids, as
being measured during in vivo experiments, which
intended to mimic situations of endogenous prednisol-
one formation and dose-variant exogenous prednisolone
administration.
Based on the plasma pharmacokinetics and urinary
profiles, it was concluded that 20β-dihydroprednisolone
is the most abundant prednisolone-derived metabolite in
both matrix types, independently of administration
route. These results are in line with the findings of Neb-
bia et al. (2014) [3], who acknowledged 20β-
dihydroprednisolone as the main urinary metabolite of
prednisolone in therapeutically treated bovines (n = 14).
As such, based on the abundant presence of 20β-
dihydroprednisolone, this metabolite was indeed consid-
ered interesting to be tested as a potential urinary
discriminative marker. In the prednisolone-treated
animals, this metabolite could be detected in all urine
samples, independently of the prednisolone administra-
tion route or dose. However, 20β-dihydroprednisolone
was also detected in all samples from the ACTH
treatment, which intended to induce endogenous forma-
tion of prednisolone. Hereby, no significant differences
(p-value > 0.05) could be revealed between the urinary
concentrations for the growth-promoting treatment and
those in the samples that were collected 6 h after tetra-
cosactide hexaacetate administration. On the other hand,
at 4 h after tetracosactide hexaacetate treatment, urinary
concentrations of 20β-dihydroprednisolone were noted
to be significantly higher (p-value < 0.05) than those ob-
tained during the growth-promoting treatment. Never-
theless, it is stated that 20β-dihydroprednisolone is no
adequate marker metabolite as its discriminative poten-
tial will be strongly dependent on the time of sampling,
relative to the triggering (stress) moment of endogenous
prednisolone formation, whereby a small shift in time
may already yield a completely different decision with
respect to the origin of detected prednisolone. Moreover,
it would be very difficult or even impossible to set a dis-
criminative threshold for 20β-dihydroprednisolone as a
large inter-individual variation in urinary concentration
was noted for this metabolite. In this regard, it can be
stated that metabolic processes and their sensitivity to
specific triggers are strongly depending on the individual
animal, which was also concluded when considering the
urinary profiles of 20α-dihydroprednisolone within the
prednisolone treatments. It was hereby observed that for
both the oral growth-promoting and therapeutic treat-
ment, the same 8 out of 12 animals showed detectable
concentration levels of 20α-dihydroprednisolone in their
urine. As this was verified to be independent of body
weight or age, individual differences in metabolism are
assumed to be responsible for this.
Evaluation of the prednisolone/cortisol ratio was con-
ducted by profiling the natural glucocorticoid metabo-
lites during dose-variant prednisolone treatments
(growth-promoting and therapeutic) as well as induced
formation of endogenous prednisolone. For the prednis-
olone treatments, a dose-dependent decrease in relative
intensities was observed for the natural urinary gluco-
corticoids, including cortisol. This indicates a significant
effect of prednisolone administration on the regulation
of the synthesis of endogenous glucocorticoids, being the
result of a suppressed hypothalamic-pituitary-adrenal axis.
Fig. 4 Heat map with the relative abundance of urinary steroids and metabolites along in vivo treatments. Within this heat map, urinary relative
abundances are presented for the acclimatization period (Blank), growth-promoting treatment (PO1 and IM1), therapeutic treatment (PO2 and
IM2), and ACTH treatment. The intensities of each ion were averaged (n = 12) and then log-transformed. Shades of black and white represent,
respectively, higher and lower intensities as observed for the different treatments
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Hereby, prednisolone inhibits the transcription of
corticotropin-releasing hormone (CRH), which also nega-
tively affects the pro-opiomelanocortin (POMC) transcrip-
tion. The associated POMC polypeptide is a precursor for
ACTH, which makes that administration of prednisolone
indirectly leads to the inhibition of ACTH and eventually
to a decreased production of cortisol [26]. The impact of
prednisolone is hereby influenced by both the dosage and
administration route [27], which has been observed in this
study as well. Focusing on the growth-promoting treat-
ment, prednisolone/cortisol ratios ranged from 0.0603 to
9.55 during PO administration and from 1.57 to 36.9 dur-
ing IM administration (Fig. 5). Metabolism of cortisol was
also monitored during pharmacologically induced stress,
triggering the hypothalamic-pituitary-adrenal axis and as-
sociated cortisol secretion. As expected, in comparison
with non-stressed conditions (i.e. Blank), a significantly
higher (p < 0.05) urinary cortisol concentration was ob-
served upon tetracosactide hexaacetate administration.
For calculation of the associated prednisolone/cortisol ra-
tios, it was opted to also incorporate the data from a re-
cent study of De Clercq et al. (2015) [28], considering a
situation of ‘natural’ stress (at slaughter). As such, concen-
tration ratios ranged from 0.00379 to 0.0763 at 4 h after
ACTH treatment, from 0.0147 to 0.129 at 6 h after ACTH
treatment, and from 0.00315 to 1.044 awaiting slaughter
(Fig. 5). Based on the increased cortisol secretion during
(induced) stress, prednisolone/cortisol ratios appeared to
be significantly lower (p-value < 0.05) than during growth-
promoting prednisolone treatment. However, it is here
also noted that ratios tend to change rapidly with the time
relative to the moment of stress. Nevertheless, this ratio
shows potential to affirm the origin of detected prednisolone,
and for this, a discriminative threshold was determined. To
this end, a receiver operating characteristics (ROC) curve
was established (Fig. 6) (SPSS Statistics 24, BMI, USA),
which described the sensitivity and specificity when deciding
on the origin of detected prednisolone. Hereby, the individ-
ual prednisolone/cortisol ratios associated with natural stress
(at slaughter, n = 36), induced stress (ACTH treatment,
n = 45), and prednisolone treatments (PO and IM, n = 103)
were used. It should be noted that only those samples with
detectable prednisolone concentrations were taken into ac-
count and that in case of cortisol concentrations below the
LOD, the ratio was set as the maximum of the concerned
experimental condition. The latter was the case for some
samples from PO and IM, and this for both therapeutic and
growth-promoting treatment. Based on the area under the
curve (AUC), which is in fact a summary measure of the
ROC-curve, excellent discrimination using the prednisolone/
cortisol ratio was concluded as the AUC was 0.945 (p-value
of 4.11 e−5) and thus close to 1 [29]. Searching the balance
between an optimal sensitivity and specificity, a threshold of
0.260 was decided, which was accompanied by a sensitivity
of 94.2% and a specificity of 99.0%. Further studies should
confirm the validity of this threshold in discriminating en-
dogenous from exogenous prednisolone.
Conclusions
This study yielded an expedient strategy to appoint the ori-
gin of detected urinary prednisolone in cattle. More
Fig. 5 Boxplot for urinary prednisolone/cortisol ratios as determined for
growth-promoting, ACTH treatment and at slaughter. Urinary
concentration ratios were log-transformed. Within the growth-promoting
treatment, a distinction between oral (PO1) and intramuscular (IM)
prednisolone treatment was made
Fig. 6 ROC-curve for sensitivity and specificity in determining the
origin of prednisolone using the prednisolone/cortisol ratio. Data for
natural stress (slaughter, n = 36), pharmacologically induced stress
(ACTH, n = 45), and exogenously administered prednisolone (PO
and IM, n = 103) were used for establishing the ROC-curve. The
diagonal line represents the class discrimination on random chance
with an AUC of 0.5 whereas a perfect discrimination is represented
by an AUC of 1. The AUC of this particular ROC curve was 0.945
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specifically, the urinary prednisolone/cortisol ratio was
found to specifically discriminate between exogenous and
endogenous prednisolone, being the result of exogenous
prednisolone administration and pharmacologically in-
duced or natural stress, respectively. Hereby, a discrimina-
tive threshold value was proposed, i.e. a concentration ratio
of 0.260, which rendered a sensitivity of 94.2% and specifi-
city of 99.0%. As such, the prednisolone/cortisol ratio is be-
lieved to hold significant value to contribute towards a
more righteous decision-making when monitoring for
unauthorized usage of prednisolone in bovine breeding.
However, it is acknowledged that the validity of the sug-
gested threshold should be verified under varying condi-
tions and on a larger scale before implementation of the
prednisolone/cortisol ratio becomes possible. Alternatively,
the discriminating potential of 20β-dihydroprednisolone
was assessed as well, whereby no unambiguously significant
concentration differences were noted between exogenous
prednisolone administration and pharmacologically in-
duced endogenous formation of prednisolone. Therefore, at
this this point, 20β-dihydroprednisolone was not assigned
any marker potential, although situations of prednisolone
formation under natural stress should be considered before
the marker potential of this metabolite can be disclaimed
definitely. In this context and in contrast with the applied
targeted approaches, an untargeted fingerprinting of the
urinary metabolome may still be opportune to reveal (un-
known) metabolite markers in order to transcend the sensi-
tivity and specificity values, as currently linked with the
prednisolone/cortisol ratio.
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